Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 26% Improvement Relative Risk Discharge 26% Hospitalization time -25% HCQ  Sarhan et al.  LATE TREATMENT  RCT Is late treatment with HCQ beneficial for COVID-19? RCT 108 patients in Egypt (October 2020 - March 2021) Trial compares with remdesivir, results vs. placebo may differ Lower mortality (p=0.39) and higher discharge (p=0.39), not sig. c19hcq.org Sarhan et al., J. Infection and Public.., Nov 2021 Favors HCQ Favors remdesivir

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients

Sarhan et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.10.024, NCT04779047
Nov 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Small 108 patient RCT comparing HCQ vs. remdesivir in very late stage treatment. All patients received tocilizumab. There were significant unadjusted baseline differences in ventilation and ICU admission. NCT04779047 (history). REC-H-PhBSU-21011.
Although the 26% lower mortality is not statistically significant, it is consistent with the significant 24% lower mortality [20‑29%] from meta analysis of the 249 mortality results to date.
This study is excluded in the after exclusion results of meta analysis: very late stage, >50% on oxygen/ventilation at baseline; significant unadjusted differences between groups.
risk of death, 25.7% lower, RR 0.74, p = 0.39, treatment 12 of 56 (21.4%), control 15 of 52 (28.8%), NNT 13.
risk of no hospital discharge, 25.7% lower, RR 0.74, p = 0.39, treatment 12 of 56 (21.4%), control 15 of 52 (28.8%), NNT 13.
hospitalization time, 25.0% higher, relative time 1.25, p = 0.06, treatment 56, control 52.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sarhan et al., 2 Nov 2021, Randomized Controlled Trial, Egypt, peer-reviewed, 8 authors, study period 1 October, 2020 - 10 March, 2021, this trial compares with another treatment - results may be better when compared to placebo, trial NCT04779047 (history).
This PaperHCQAll
Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
Rania M Sarhan, Hadeer S Harb, Ahmed E Abou Warda, Mounir M Salem-Bekhit, Faiyaz Shakeel, Sami Ali Alzahrani, Yasmin M Madney, Marian S Boshra
Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.10.024
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Declarations of interest None Author contributions Original J o u r n a l P r e -p r o o f
References
Agdamag, Edmiston, Charpentier, Chowdhury, Fraser et al., Update on COVID-19 myocarditis, Medicina
Atallah, Nekidy, Mallah, Cherfan, Abdelwareth et al., Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Façade for prognostic markers, Thrombosis Journal
Ayerbe, Risco-Risco, Ayis, The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients, Internal and Emergency Medicine
Brown, Won, Graham, Dinnon, Kh et al., Broad-spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase, Antiviral research
Chen, Liu, Liu, Liu, Xu et al., A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19, Journal of Zhejiang University (Medical Science)
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, The lancet
Cichoż-Lach, Michalak, Liver injury in the era of COVID-19, World Journal of Gastroenterology
Clancy, Nguyen, Coronavirus disease 2019, superinfections, and antimicrobial development: what can we expect?, Clinical Infectious Diseases
Elsawah, Elsokary, Abdallah, Elshafie, Ohl et al., Efficacy and safety of remdesivir in hospitalized Covid-19 patients: systematic review and meta-analysis including network meta-analysis, Reviews in medical virology
Fu, Xu, Wei, Why tocilizumab could be an effective treatment for severe COVID-19?, Journal of translational medicine
Gallo Marin, Aghagoli, Lavine, Yang, Siff et al., Predictors of COVID-19 severity: A literature review, Reviews in medical virology
Gatti, Fusaroli, Caraceni, Poluzzi, Ponti et al., Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19, British Journal of Clinical Pharmacology
Giambenedetto, Ciccullo, Borghetti, Gambassi, Landi et al., Off-label use of tocilizumab in patients with SARS-CoV-2 infection, Journal of medical virology
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy, Jama
Guan, Ni, -Y, Hu, Liang et al., Tocilizumab for treatment of mechanically ventilated patients with COVID-19, New England Journal of Medicine
Idhrees, Suthakaran, Valooran, Bashir, Will Remdesivir Reshape Cardiovascular Practice in COVID 19 Era?, International Journal of Angiology
J O U R N A L P R E -P R O O F ; Grein, Ohmagari, Shin, Diaz, Asperges et al., Compassionate use of remdesivir for patients with severe Covid-19, New England Journal of Medicine
Jiang, Wang, Li, Hong, Ru et al., Liver injury in critically ill and noncritically ill COVID-19 patients: a multicenter, retrospective, observational study, Frontiers in Medicine
Jung, Bobba, Su, Shariati-Sarabi, Gladman et al., The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus, Arthritis & Rheumatism
Kafaja, Clements, Wilhalme, Tseng, -H et al., Reliability and minimal clinically important differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II). American journal of respiratory and critical care medicine
Kashour, Riaz, Garbati, Aldosary, Tlayjeh et al., Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and metaanalysis, Journal of Antimicrobial Chemotherapy
Klopfenstein, Zayet, Lohse, Balblanc, Badie et al., Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients, Médecine et Maladies Infectieuses
Lozano-Sepulveda, Galan-Huerta, Martínez-Acuña, Soto, Rivas-Estilla, SARS-CoV-2 another kind of liver aggressor, how does it do that?, Annals of Hepatology
Luo, Liu, Qiu, Liu, Liu et al., Tocilizumab treatment in COVID-19: A singlecenter experience, Journal of medical virology
Manocha, Kirzner, Ying, Yeo, Peltzer et al., Troponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized With COVID-19: Derivation and Validation of the HA2T2 COVID-19 Mortality Risk Score, Journal of the American Heart Association
Martinot, Jary, Fafi-Kremer, Leducq, Delagreverie et al., Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19
Mccreary, Angus, Efficacy of Remdesivir in COVID-19, Jama
Mehta, An, Andersen, Mansour, Madhira et al., Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States: A Retrospective Cohort Study, Annals of internal medicine
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel medicine and infectious disease
Mulangu, Dodd, Jr, Mbaya, Proschan et al., A randomized, controlled trial of Ebola virus disease therapeutics, New England Journal of Medicine
Rafaniello, Ferrajolo, Sullo, Gaio, Zinzi et al., Cardiac events potentially associated to remdesivir: An analysis from the european spontaneous adverse event reporting system, Pharmaceuticals
Sarhan, Madney, Warda, Boshra, Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab, International journal of clinical practice
Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases, The Lancet infectious diseases
Scavone, Brusco, Bertini, Sportiello, Rafaniello et al., Current pharmacological treatments for COVID-19: what's next?, British journal of pharmacology
Sciascia, Aprà, Baffa, Baldovino, Boaro et al., Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19, Clin Exp Rheumatol
Scott, Tocilizumab: a review in rheumatoid arthritis, Drugs
Scully, Haverfield, Ursin, Tannenbaum, Klein, Considering how biological sex impacts immune responses and COVID-19 outcomes, Nature Reviews Immunology
Serviddio, Villani, Stallone, Scioscia, Foschino-Barbaro et al., ? covid19?> Tocilizumab and liver injury in patients with COVID-19, Therapeutic Advances in Gastroenterology
Spinner, Gottlieb, Criner, López, Cattelan et al., Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, Jama
Tirupathi, Bharathidasan, Areti, Kaur, Salim et al., The shortcomings of tocilizumab in COVID-19, Infez Med
Vegivinti, Pederson, Saravu, Gupta, Barrett et al., Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials, Annals of Medicine and Surgery
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell research
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, Jama
Wang, Liu, Liu, Li, Lin et al., SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19, Journal of hepatology
Whittington, Campbell, Alternative pricing models for remdesivir and other potential treatments for COVID-19, Institute for Clinical and Economic Review
Williamson, Walker, Bhaskaran, Bacon, Bates et al., Factors associated with COVID-19-related death using OpenSAFELY, Nature
Xu, Han, Li, Sun, Wang et al., Effective treatment of severe COVID-19 patients with tocilizumab, Proceedings of the National Academy of Sciences
Yang, Yu, Xu, Shu, Liu et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, The Lancet Respiratory Medicine
Yapali, What hepatologists need to know about COVID-19?, Hepatology
Zampino, Mele, Florio, Bertolino, Andini et al., Liver injury in remdesivir-treated COVID-19 patients, Hepatology international
Zangrillo, Beretta, Scandroglio, Monti, Fominskiy et al., None
Zhao, Ni, Gao, Wang, Yang et al., Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids, Protein & cell
Zhou, Yu, Du, Fan, Liu et al., a retrospective cohort study
Ziaie, Koucheck, Miri, Salarian, Shojaei et al., Review of therapeutic agents for the treatment of COVID-19, Journal of Cellular & Molecular Anesthesia
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit